TPTH Tripath Imaging

Cumulative Commitments to SurePath Now Nearly 36% of Market BURLINGTON, N.C., Dec. 8 /PRNewswire-FirstCall/ -- TriPath Imaging, Inc. (NASDAQ:TPTH) today announced that Medical Solutions plc, its licensed distributor in the United Kingdom (U.K.), has been awarded a five-year contract to supply the SurePath(TM) liquid-based Pap test to the South Yorkshire Cytology Trusts. "We are very pleased that the U.K. continues to adopt the SurePath liquid- based Pap test," said Ray Swanson, Senior Vice President of Commercial Operations of TriPath Imaging. "With this contract, we now have cumulative commitments that represent nearly 36% of the market in the U.K., 38% in England and Wales. We expect to continue to grow our opportunity in the U.K. as other regions finalize their decisions." About TriPath Imaging, Inc. TriPath Imaging, Inc., headquartered in Burlington, North Carolina, develops, manufactures, markets and sells innovative solutions to improve the clinical management of cancer, including detection, diagnosis, staging and treatment. TriPath Oncology, a wholly owned subsidiary of TriPath Imaging, develops molecular diagnostic products for malignant melanoma and cancers of the cervix, breast, ovary and prostate. Investors are cautioned that statements in this press release that are not strictly historical statements constitute forward-looking statements which involve risks and uncertainties that could cause actual results and outcomes to differ materially from what is expressed in those forward-looking statements. Such forward-looking statements include, without limitation, those related to the scheduled rollout of its tests in the South Yorkshire Cytology Trusts of England expected growth in the U.K. Important factors that may affect TriPath Imaging's operating results include, without limitation: TriPath Imaging may not receive revenues when or in the amounts anticipated; TriPath Imaging may be unable to increase sales and revenues at its historical rates; TriPath Imaging and TriPath Oncology's products may not receive FDA or other required regulatory approval when expected, if at all; TriPath Imaging may be unable to increase its penetration of the large commercial laboratories to the extent it expects while maintaining its business with its traditional customer base, and may not achieve revenues to the degree expected from the sale of reagents and instrument systems derived from its molecular oncology development program; TriPath Imaging's expanding sales and marketing presence may not have the expected impact and may face attrition issues customary for such an expansion; TriPath Imaging's results and profitability in any particular period may be impacted by the timing of certain non-cash sales discounts that TriPath Imaging will record in connection with the vesting of certain warrants; expenses may exceed expectations and TriPath Imaging may not maintain profitability; changes in general economic conditions or the healthcare industry may occur that adversely affect TriPath Imaging's customers' purchasing plans; competition and competitive pricing pressures may limit TriPath Imaging's flexibility with respect to the pricing of its products; TriPath Imaging may need to obtain additional financing in the future; TriPath Imaging may not be able to develop and to protect adequately its proprietary technology; and other risks detailed in TriPath Imaging's filings with the Securities and Exchange Commission, including those described in TriPath Imaging's Annual Report on Form 10-K for the year ended December 31, 2004. Contacts Stephen P. Hall Chief Financial Officer (336) 290-8721 DATASOURCE: TriPath Imaging, Inc. CONTACT: Stephen P. Hall, Chief Financial Officer, +1-336-290-8721 Web site: http://www.tripathimaging.com/

Copyright